PRAX – praxis precision medicines, inc. (US:NASDAQ)
Stock Stats
News
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $250.00 price target on the stock.
Form 4 Praxis Precision Medicin For: Nov 20 Filed by: Nemiroff Alex
Form 4 Praxis Precision Medicin For: Nov 14 Filed by: Kelly Timothy Edwin
Form 4 Praxis Precision Medicin For: Nov 20 Filed by: Mastrocola Lauren
Form 144 Praxis Precision Medicin Filed by: Nemiroff Alex
Form 144 Praxis Precision Medicin Filed by: Mastrocola Lauren
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.